Skip to main content
Equibles
NPCE logo

NPCE · NeuroPace Inc · Webcasts, Transcripts & Audio

Track NPCE — free

Use NPCE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NPCE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.91 -0.23 (-1.75%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$443.13M
Shares
34.32M
Volume · Oct 23 69.07K Avg daily vol (3M) 157.8K

NeuroPace Inc Webcasts

Earnings calls, investor updates, investor days and conferences for NeuroPace Inc (NPCE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-08
NeuroPace Inc (NPCE) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-11
NeuroPace Inc (NPCE) Q2 2026 Earnings Call Transcript
Positive tone IGE PMA supplement / FDA interaction Updated 2026 financial guidance ECOG Assistant product launch
Revenue
$22.83M
▲ 17.1% YoY
Diluted EPS
$-0.18
Gross margin
82.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
NeuroPace Inc (NPCE) Q1 2026 Earnings Call Transcript
Confident tone Reimbursement landscape IGE / NAUTILUS PMA supplement review Commercial execution and prescriber growth
Revenue
$22.07M
▼ 2% YoY
Diluted EPS
$-0.20
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-14
NeuroPace Inc (NPCE) April 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-11
NeuroPace Inc (NPCE) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-03
NeuroPace Inc (NPCE) Q4 2025 Earnings Call Transcript
Confident tone Idiopathic generalized epilepsy (IGE) indication expansion Profitability and cash generation Core RNS business growth
Revenue
$30.61M*
▲ 42.6% YoY
Gross margin
73.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
NeuroPace Inc (NPCE) Q3 2025 Earnings Call Transcript
Confident tone NAUTILUS IGE Indication and FDA RNS Platform and Closed-Loop Technology Project CARE and Market Expansion
Revenue
$27.35M
▲ 29.9% YoY
Diluted EPS
$-0.11
Gross margin
77.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
NeuroPace Inc (NPCE) Q2 2025 Earnings Call Transcript
Confident tone Project CARE community expansion NAUTILUS IGE pivotal trial and FDA submission Revenue growth and record results
Revenue
$19.50M
▲ 1.3% YoY
Diluted EPS
$-0.26
Gross margin
83.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
NeuroPace Inc (NPCE) Q1 2025 Earnings Call Transcript
Confident tone SEEG / DIXI Distribution Wind-Down RNS Revenue Growth Clinical Development Programs
Revenue
$22.52M
▲ 24.3% YoY
Diluted EPS
$-0.21
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
NeuroPace Inc (NPCE) Q4 2024 Earnings Call Transcript
Confident tone Revenue growth and financial performance Active prescribers and adoption in CECs Nautilus idiopathic generalized epilepsy pivotal study
Revenue
$21.47M*
▲ 19.2% YoY
Gross margin
75.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
NeuroPace Inc (NPCE) Q3 2024 Earnings Call Transcript
Confident tone Project CARE pilot and site of service expansion Revenue growth and RNS System adoption Gross margin and operating expense discipline
Revenue
$21.06M
▲ 28.2% YoY
Diluted EPS
$-0.19
Gross margin
73.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
NeuroPace Inc (NPCE) Q2 2024 Earnings Call Transcript
Positive tone Revenue Growth and RNS Sales Three-Phase Growth Strategy Gross Margin Performance
Revenue
$19.26M
▲ 16.6% YoY
Diluted EPS
$-0.26
Gross margin
73.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
NeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript
Confident tone RNS System revenue growth and adoption Total addressable market and long-term opportunity DIXI Medical partnership
Revenue
$18.12M
▲ 25.2% YoY
Diluted EPS
$-0.32
Gross margin
73.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
NeuroPace Inc (NPCE) Q4 2023 Earnings Call Transcript
Confident tone RNS system revenue growth DIXI Medical diagnostic electrodes partnership Three-part growth strategy / modern RNS story
Revenue
$18.01M*
▲ 40.8% YoY
Gross margin
75.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
NeuroPace Inc (NPCE) Q3 2023 Earnings Call Transcript
Revenue
$16.43M
▲ 47.2% YoY
Diluted EPS
$-0.28
Gross margin
74.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
NeuroPace Inc (NPCE) Q2 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 61.9% YoY
Diluted EPS
$-0.36
Gross margin
72.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
NeuroPace Inc (NPCE) Q1 2023 Earnings Call Transcript
Revenue
$14.47M
▲ 27.2% YoY
Diluted EPS
$-0.41
Gross margin
71.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
NeuroPace Inc (NPCE) Q4 2022 Earnings Call Transcript
Revenue
$12.79M*
▲ 16.3% YoY
Gross margin
68.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
NeuroPace Inc (NPCE) Q3 2022 Earnings Call Transcript
Revenue
$11.16M
▲ 7.9% YoY
Diluted EPS
$-0.48
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
NeuroPace Inc (NPCE) Q2 2022 Earnings Call Transcript
Revenue
$10.20M
▼ 19.2% YoY
Diluted EPS
$-0.52
Gross margin
73.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
NeuroPace Inc (NPCE) Q1 2022 Earnings Call Transcript
Revenue
$11.37M
▲ 1.4% YoY
Diluted EPS
$-0.47
Gross margin
72.6%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
NeuroPace Inc (NPCE) Q4 2021 Earnings Call Transcript
Revenue
$11.00M*
▲ 2.3% YoY
Gross margin
73.4%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
NeuroPace Inc (NPCE) Q3 2021 Earnings Call Transcript
Revenue
$10.34M
▼ 19% YoY
Diluted EPS
$-0.34
Gross margin
72.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
NeuroPace Inc (NPCE) Q2 2021 Earnings Call Transcript
Revenue
$12.63M
▲ 65.3% YoY
Diluted EPS
$-0.48
Gross margin
74.1%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-06-03
NeuroPace Inc (NPCE) Q1 2021 Earnings Call Transcript
Revenue
$11.22M
▲ 12.5% YoY
Diluted EPS
$-32.73
Gross margin
75.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1528287 CUSIP 641288105 13F (30d) 7 filings 7 filers Visit website Investor relations